{
    "clinical_study": {
        "@rank": "151563", 
        "brief_summary": {
            "textblock": "To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine\n      plus lamivudine."
        }, 
        "brief_title": "A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus\n      lamivudine until the completion of the analysis after at least 4 weeks of therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV antibody positive.\n\n          -  CD4 count >= 150 and <= 500 cells/mm3.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior antiretroviral therapy.\n\n          -  Prior protease inhibitor therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002190", 
            "org_study_id": "229N", 
            "secondary_id": "NV15114"
        }, 
        "intervention": [
            {
                "intervention_name": "Saquinavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Saquinavir", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Zidovudine", 
            "HIV Protease Inhibitors", 
            "Lamivudine", 
            "Saquinavir", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94114"
                    }, 
                    "name": "Davies Med Ctr / c/o HIV Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sherman Oaks", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91403"
                    }, 
                    "name": "Pacific Oaks Med Group / Rsch & Scientific Investigation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia Presbyterian Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002190"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1997"
    }, 
    "geocoordinates": {
        "Columbia Presbyterian Med Ctr": "40.714 -74.006", 
        "Davies Med Ctr / c/o HIV Institute": "37.775 -122.419", 
        "Pacific Oaks Med Group / Rsch & Scientific Investigation": "34.149 -118.451"
    }
}